Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Structure of the Epstein-Barr virus major envelope glycoprotein.

Szakonyi G, Klein MG, Hannan JP, Young KA, Ma RZ, Asokan R, Holers VM, Chen XS.

Nat Struct Mol Biol. 2006 Nov;13(11):996-1001. Epub 2006 Oct 29.

PMID:
17072314
2.

Isolating the Epstein-Barr virus gp350/220 binding site on complement receptor type 2 (CR2/CD21).

Young KA, Chen XS, Holers VM, Hannan JP.

J Biol Chem. 2007 Dec 14;282(50):36614-25. Epub 2007 Oct 9.

3.

Molecular basis of the interaction between complement receptor type 2 (CR2/CD21) and Epstein-Barr virus glycoprotein gp350.

Young KA, Herbert AP, Barlow PN, Holers VM, Hannan JP.

J Virol. 2008 Nov;82(22):11217-27. doi: 10.1128/JVI.01673-08. Epub 2008 Sep 10.

6.

Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2.

Martin DR, Yuryev A, Kalli KR, Fearon DT, Ahearn JM.

J Exp Med. 1991 Dec 1;174(6):1299-311.

8.
9.

Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220.

Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD.

J Immunol. 2001 Aug 1;167(3):1490-9.

10.
11.

Epitope mapping using the X-ray crystallographic structure of complement receptor type 2 (CR2)/CD21: identification of a highly inhibitory monoclonal antibody that directly recognizes the CR2-C3d interface.

Guthridge JM, Young K, Gipson MG, Sarrias MR, Szakonyi G, Chen XS, Malaspina A, Donoghue E, James JA, Lambris JD, Moir SA, Perkins SJ, Holers VM.

J Immunol. 2001 Nov 15;167(10):5758-66.

12.

Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis.

Tanner J, Weis J, Fearon D, Whang Y, Kieff E.

Cell. 1987 Jul 17;50(2):203-13.

PMID:
3036369
13.

Soluble gp350/220 and deletion mutant glycoproteins block Epstein-Barr virus adsorption to lymphocytes.

Tanner J, Whang Y, Sample J, Sears A, Kieff E.

J Virol. 1988 Dec;62(12):4452-64.

14.

Identification of three gp350/220 regions involved in Epstein-Barr virus invasion of host cells.

Urquiza M, Lopez R, PatiƱo H, Rosas JE, Patarroyo ME.

J Biol Chem. 2005 Oct 21;280(42):35598-605. Epub 2005 Aug 8.

15.

Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.

Hedrick JA, Lao Z, Lipps SG, Wang Y, Todd SC, Lambris JD, Tsoukas CD.

J Immunol. 1994 Nov 15;153(10):4418-26.

PMID:
7963519
17.

Patterned entry and egress by Epstein-Barr virus in polarized CR2-positive epithelial cells.

Chodosh J, Gan Yj, Holder VP, Sixbey JW.

Virology. 2000 Jan 20;266(2):387-96.

18.

Cloning and analysis of the Epstein-Barr virus glycoprotein 350 genes.

Chang SH, Kim SH, Lee WK, Kim HJ, Choi SH, Park JH, Jang HS, Chung GH, Kwon TH, Kim DH, Yang MS, Jang YS.

Mol Cells. 1998 Oct 31;8(5):585-93. Erratum in: Mol Cells 1999 Feb 28;9(1):following 114.

19.

Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2).

Moore MD, DiScipio RG, Cooper NR, Nemerow GR.

J Biol Chem. 1989 Dec 5;264(34):20576-82.

20.

Structural studies in solution of the recombinant N-terminal pair of short consensus/complement repeat domains of complement receptor type 2 (CR2/CD21) and interactions with its ligand C3dg.

Guthridge JM, Rakstang JK, Young KA, Hinshelwood J, Aslam M, Robertson A, Gipson MG, Sarrias MR, Moore WT, Meagher M, Karp D, Lambris JD, Perkins SJ, Holers VM.

Biochemistry. 2001 May 22;40(20):5931-41.

PMID:
11352728
Items per page

Supplemental Content

Write to the Help Desk